Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2, 3-dioxygenase (IDO) is an inflammatory cytokine-inducible rate-limiting enzyme of the tryptophan (Trp) catabolism, which is involved in the inhibition of intracellular pathogen replication as well as in immunomodulation. To date, three types of tryptophan-metabolizing enzymes have been identified: IDO1, IDO2 and tryptophan 2,3-dioxygenase 2.

IDO is an intracellular enzyme that is constitutively expressed in several human and mouse cells. Being present in innate immune cells, such as Mos and dendritic cells (DCs), IDO catalyzes the initial rate-limiting step of tryptophan (Trp) catabolism, thus leading to the production of immunoregulatory catabolites (collectively known as kynurenines).

The IDO gene promoter contains multiple sequence elements that confer responsiveness to proinflammatory mediators, thereby demonstrating the strong correlation between inflammation and induced IDO expression.

Indoleamine 2,3-Dioxygenase (IDO) Inhibitors

(Rac)-IDO1-IN-5

Cat. No.: HY-111540A

(Rac)-IDO1-IN-5 (Example 1) is a racemate of IDO1-IN-5. IDO1-IN-5 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(Rac)-Indoximod

(1-Methyl-DL-tryptophan; (Rac)-NLG-8189)

Cat. No.: HY-133897

(Rac)-Indoximod (1-Methyl-DL-tryptophan) is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

(S)-IDO1-IN-5

Cat. No.: HY-111540B

(S)-IDO1-IN-5 (Example 1B) is an active S-isomer of IDO1-IN-5. (S)-IDO1-IN-5 binds to **IDOL** with an IC_{50} value less than 1.5 μM.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(S)-Indoximod

(1-Methyl-L-tryptophan; (S)-NLG-8189)

Cat. No.: HY-N0707

(S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of **indoleamine 2,3-dioxygenase (IDO)**. (S)-Indoximod can be used for the research of cancer.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 100 mg

(S)-Indoximod-d3

(1-Methyl-L-tryptophan-d3; (S)-NLG-8189-d3)

Cat. No.: HY-N0707S

(S)-Indoximod-d3 is the deuterium labeled (S)-Indoximod. (S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO). (S)-Indoximod can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-986242

Cat. No.: HY-139204

BMS-986242 is an orally active, potent and selective indoleamine-2,3-dioxygenase 1 (**IDO1**) inhibitor. BMS-986242 can be used for the research of cancer.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMT-297376

Cat. No.: HY-139205

BMT-297376, the optimized Linrodostat, is a potent **IDO1** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Coptisine

(Coptisin)

Cat. No.: HY-N0430

Coptisine is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive **IDO** inhibitor with a K_i value of 5.8 μM and an IC_{50} value of 6.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Coptisine chloride

Cat. No.: HY-N0736

Coptisine chloride is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive **IDO** inhibitor with a K_i value of 5.8 μM and an IC_{50} value of 6.3 μM.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Coptisine Sulfate

Cat. No.: HY-N0430A

Coptisine Sulfate is an alkaloid from Chinese goldthread, and acts as an efficient uncompetitive **IDO** inhibitor with a K_i value of 5.8 μM and an IC_{50} value of 6.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Epacadostat

(INCB 024360) Cat. No.: HY-15689

Epacadostat (INCB 024360) is a potent and selective **indoleamine 2,3-dioxigenase 1 (IDO1)** inhibitor with an IC_{50} of 71.8 nM.



Purity: 99.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GNF-PF-3777

(8-Nitrotryptanthrin) Cat. No.: HY-100687

GNF-PF-3777 (8-Nitrotryptanthrin) is a potent human **indoleamine 2,3-dioxygenase** 2 (h**IDO2**) inhibitor which significantly reduces IDO2 activity with K_i of 0.97 μM.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

HI5

Cat. No.: HY-146261

HI5 is a potent **tublin** and **IDO** inhibitor, with an IC_{50} value of 70 nM in HeLa cells. HI5 inhibit IDO expression and decrease kynurenine production, leading to stimulating T cells activation and proliferation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IACS-8968

(IDO/TDO Inhibitor) Cat. No.: HY-112164

IACS-8968 (IDO/TDO Inhibitor) is a dual **IDO** and **TDO** inhibitor, with **pIC$_{50}$s** of 6.43 for IDO and <5 for TDO, respectively.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

IACS-8968 R-enantiomer

(IDO/TDO Inhibitor (R-enantiomer)) Cat. No.: HY-112164A

IACS-8968 (R-enantiomer) is the R-enantiomer of IACS-8968. IACS-8968 is a dual **IDO** and **TDO** inhibitor, with **pIC$_{50}$s** of 6.43 for IDO and <5 for TDO, respectively.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

IACS-8968 S-enantiomer

(IDO/TDO Inhibitor (S-enantiomer)) Cat. No.: HY-112164B

IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual **IDO** and **TDO** inhibitor, with **pIC$_{50}$s** of 6.43 for IDO and <5 for TDO, respectively.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

IDO-IN-1

Cat. No.: HY-79531

IDO-IN-1 is a potent indoleamine 2,3-dioxygenase (**IDO**) inhibitor with an IC_{50} of 59 nM.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

IDO-IN-11

Cat. No.: HY-111234

IDO-IN-11 is an indoleamine-2,3-dioxygenase (**IDO**) inhibitor with IC_{50}s of 0.18 μM (Kinase) and 0.014 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 13.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO-IN-12

Cat. No.: HY-115122

IDO-IN-12 is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor extracted from patent WO 2017181849 A1.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

IDO-IN-13

Cat. No.: HY-129749

IDO-IN-13 is a potent **indoleamine 2,3-dioxygenase 1 (IDO1)** inhibitor with an EC_{50} of 17 nM, extracted from patent WO2019040102A1, example 43.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO-IN-14

Cat. No.: HY-139653

IDO-IN-14 is an **IDO** inhibitor with an IC_{50} value of 0.6928 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO-IN-15

Cat. No.: HY-139883

IDO-IN-15 is an **IDO1** inhibitor (IC_{50} < 0.51 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO-IN-16

Cat. No.: HY-142933

IDO-IN-16 (compound 5) is an **IDO** inhibitor, with an IC_{50} of 36 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO-IN-3

Cat. No.: HY-16987

IDO-IN-3 is a potent indoleamine 2,3-dioxygenase (**IDO**) inhibitor with an IC_{50} of 290 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

IDO-IN-4

Cat. No.: HY-18769

IDO-IN-4 is an indoleamine 2,3-dioxygenase 1 (**IDO-1**) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 50 mg

IDO-IN-5
(NLG-1489)

Cat. No.: HY-18770

IDO-IN-5 (NLG-1489) is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor extracted from patent WO WO2012142237A1, compound 1489, has an IC_{50} of 1-10 μM.



Purity: 95.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

IDO-IN-6
(NLG-1486)

Cat. No.: HY-18770A

IDO-IN-6 (NLG-1486) is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor extracted from patent WO WO2012142237A1, Compound 1486, has an IC_{50} of <1 μM.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

IDO-IN-7
(NLG-919 analogue; GDC-0919 analogue)

Cat. No.: HY-13983

IDO-IN-7 (NLG-919 analogue) is a a potent **IDO1** inhibitor with an IC_{50} of 38 nM.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

IDO-IN-8
(NLG-1487)

Cat. No.: HY-18770C

IDO-IN-8 (NLG-1487) is an indoleamine 2,3-dioxygenase (**IDO**) inhibitor extracted from patent WO WO2012142237A1, compound 1487, has an IC_{50} of 1-10 μM.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

IDO-IN-9

Cat. No.: HY-110387

IDO-IN-9 is an indoleamine-2,3-dioxygenase (**IDO**) inhibitor with IC_{50}s of 0.011 μM (Kinase) and 0.0018 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 6.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO/TDO-IN-1

Cat. No.: HY-128355

IDO/TDO-IN-1 (compound 25) is a highly potent and orally active dual **indoleamine-2,3-dioxygenase (IDO)** and **tryptophan 2,3-dioxygenase (TDO)** inhibitor with IC_{50}s of 9.7 and 47 nM, respectively .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1 and HDAC1 Inhibitor

Cat. No.: HY-112147

IDO1 and HDAC1 Inhibitor (Compound 10) is a dual **IDO1** and **HDAC1** inhibitor with IC_{50}s of 69.0 nM and 66.5 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-11

Cat. No.: HY-145332

IDO1-IN-11 is an **IDO1** inhibitor with an IC_{50} value of 0.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-12

Cat. No.: HY-145355

IDO1-IN-12 is a potent and orally available **IDO1** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-13

Cat. No.: HY-144273

IDO1-IN-13 (compound 27a) is a potent **IDO1** inhibitor with an IC_{50} of 61.6 nM. IDO1-IN-13 has cellular IDO1 inhibition (HeLa EC_{50}= 30 nM). IDO1-IN-13 decreases 51% of the kyn/trp ratio in SK-OV-3 xenograft tumor tissues.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-14

Cat. No.: HY-144274

IDO1-IN-14 (compound 4a) is a potent **IDO1** inhibitor with an IC_{50} of 396.9 nM. IDO1-IN-14 has cellular IDO1 inhibition (HeLa EC_{50}=3393 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-15

Cat. No.: HY-144465

IDO1-IN-15 is a potent **IDO1** inhibitor (IC_{50}=127 nM). IDO1-IN-15 has comparable potency against IDO1 enzyme in vitro with Epacadostat.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-16

Cat. No.: HY-144466

IDO1-IN-16 (I-1) is an **IDO1** inhibitor targeting holo-IDO1, with an IC_{50} of 127 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-17

Cat. No.: HY-144468

IDO1-IN-17 (I-4) is an **IDO1** inhibitor, with an IC_{50} of 0.44 μM in hela cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-2

Cat. No.: HY-130607

IDO1-IN-2 (compound 16) is a potent and selective **IDO1** inhibitor with IC_{50}s of 81 nM, 59 nM (mouse) and 28 nM (rat), respectively. IDO1-IN-2 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-20

Cat. No.: HY-146215

Hy-146215 is an enzyme that catalyzes the oxidative metabolism of tryptophan. It can immunosuppress tumors in the tumor microenvironment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1-IN-5

Cat. No.: HY-111540

IDO1-IN-5 is a potent, selective and brain penetrated inhibitor of **IDO1** activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IDO1-IN-7

Cat. No.: HY-134583

IDO1-IN-7 is a highly potent and selective **indoleamine-2,3-dioxygenase-1 (IDO1)** inhibitor, with an IC_{50} of 6.1 nM in in the cellular assay (SKOV3). IDO1-IN-7 has immunomodulatory effects. IDO1-IN-7 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1/2-IN-1

Cat. No.: HY-145280

IDO1/2-IN-1 (compound 4t) is the first potent **IDO1/IDO2** dual inhibitor with IC_{50}s of 28 nM and 144 nM for IDO1 and IDO2, respectively. IDO1/2-IN-1 exhibits antitumor activies. Orally active.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO1/TDO-IN-1

Cat. No.: HY-144778

IDO1/TDO-IN-1 (30) is a potent dual **IDO1** (uncompetitive, K_i of 0.23 μM) and **TDO** (competitive, K_i of 0.73 μM) inhibitor. IDO1/TDO-IN-1 (30) significantly promotes cell apoptosis through the potential mitochondria-mediated Bcl-2/Bax pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IDO5L

Cat. No.: HY-15683

IDO5L is a potent indoleamine 2,3-dioxygenase (**IDO**) inhibitor with an IC_{50} of 67 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg, 1 g

Indoximod

(1-Methyl-D-tryptophan; NLG-8189)

Cat. No.: HY-16724

Indoximod (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (**IDO**) pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. Indoximod is an immunometabolic adjuvant used for the research of cancer.



Purity: 99.39%
Clinical Data: Phase 2
Size: 250 mg

Kushenol E

Cat. No.: HY-N2463

Kushenol E is a class of flavonoids isolated from Sophora flavescens and is a non-competitive **indoleamine 2,3-dioxygenase 1 (IDO1)** inhibitor with an IC_{50} of 7.7μM and a K_i of 9.5μM, has anti-tumor activity.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Linrodostat

(BMS-986205; ONO-7701)

Cat. No.: HY-101560

Linrodostat (BMS-986205) is a selective and irreversible **indoleamine 2,3-dioxygenase 1 (IDO1)** inhibitor with an IC_{50} value of 1.1 nM in **IDO1**-HEK293 cells. Linrodostat is well tolerated with potent pharmacodynamic activity in advanced cancers.



Purity: 99.89%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

Navoximod

(GDC-0919; NLG-919)

Cat. No.: HY-18770B

Navoximod (GDC-0919; NLG-919) is a potent **IDO** (indoleamine-(2,3)-dioxygenase) pathway inhibitor with K_i/EC_{50} of 7 nM/75 nM.



Purity: 99.99%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Necrostatin-1

(Nec-1)

Cat. No.: HY-15760

Necrostatin-1 (Nec-1) is a potent necroptosis inhibitor with an **EC_{50}** of 490 nM in Jurkat cells. Necrostatin-1 inhibits **RIP1 kinase** (**EC_{50}**=182 nM). Necrostatin-1 is also an **IDO** inhibitor.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

NLG802

Cat. No.: HY-145346

NLG802 is a prodrug of indoximod, an orally active **indoleamine 2,3-dioxygenase (IDO)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palmatine

Cat. No.: HY-N0110A

Palmatine is an orally active and irreversible **indoleamine 2,3-dioxygenase 1 (IDO-1**) inhibitor. Palmatine can ameliorate DSS (Dextran Sulphate Sodium Salt)-induced colitis by mitigating colonic injury, preventing gut microbiota dysbiosis, and regulating tryptophan catabolism.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 20 mg

Palmatine chloride

Cat. No.: HY-N0110

Palmatine chloride is an orally active and irreversible **indoleamine 2,3-dioxygenase 1 (IDO-1)** inhibitor.



Purity: 99.57%
Clinical Data: Launched
Size: 10 mM × 1 mL, 250 mg, 1 g

PCC0208009

Cat. No.: HY-100771

PCC0208009 is a potent **IDO** inhibitor with an **IC_{50}** value of 4.52 nM in HeLa cell. PCC0208009 alleviates neuropathic pain and comorbidities by regulating synaptic plasticity of anterior cingulate cortex (ACC) and amygdala .



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

PF-06840003

(EOS200271)

Cat. No.: HY-101111

PF-06840003 (EOS200271) is a highly selective orally bioavailable **IDO-1** inhibitor with **IC_{50}**s of 0.41 μM, 0.59 μM, and 1.5 μM for hIDO-1, dIDO-1, and mIDO-1, respectively.



Purity: 99.79%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PROTAC IDO1 Degrader-1

Cat. No.: HY-131911

PROTAC IDO1 Degrader-1 is the first potent **IDO1** (**indoleamine 2,3-dioxygenase 1**) degrader that hijacks IDO1 to **Cereblon** E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (**DC_{50}**=2.84 μM).

Purity: 98.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg